Of 646 patients with multiple myeloma who have received at least 1 prior therapy, 318 patients were treated with combination therapy of Caelyx 30 mg/ m2 as a one hour intravenous infusion administered on day 4 following bortezomib which is administered at 1.3 mg/ m² on days 1, 4, 8, and 11, every three weeks or with bortezomib monotherapy in a phase III clinical trial.